Compare Abeona Therapeutics Inc (ABEO) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares International Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while iShares International Treasury Bond ETF trades at $40.55. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | IGOV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $43.09 |
52-Week Low | $4.17 | $40.54 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IGOV trades at $40.75, down 0.71% today, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins. Recent news highlights institutional interest, with DMC Group increasing its stake by 69.5% in Q1 2026, but also notes downside risks from global inflationary pressures affecting its bond holdings.
The outlook remains cautious due to technical bearishness and macroeconomic headwinds, though institutional accumulation may provide some support. Key risks include interest rate sensitivity and geopolitical tensions, warranting close monitoring of earnings and economic indicators for any turnaround signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
